Pfizer, Inc. (NYSE:PFE) – Research analysts at SunTrust Banks cut their Q4 2017 earnings per share (EPS) estimates for Pfizer in a research note issued on Monday. SunTrust Banks analyst J. Boris now expects that the biopharmaceutical company will post earnings of $0.57 per share for the quarter, down from their previous forecast of $0.60. SunTrust Banks also issued estimates for Pfizer’s FY2019 earnings at $2.78 EPS, FY2020 earnings at $2.76 EPS and FY2021 earnings at $2.84 EPS.
Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 earnings per share.
ILLEGAL ACTIVITY NOTICE: “Pfizer, Inc. to Post Q4 2017 Earnings of $0.57 Per Share, SunTrust Banks Forecasts (PFE)” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2017/10/28/pfizer-inc-to-post-q4-2017-earnings-of-0-57-per-share-suntrust-banks-forecasts-pfe.html.
PFE has been the subject of a number of other reports. Sanford C. Bernstein set a $39.00 price target on Pfizer and gave the stock a “buy” rating in a report on Monday, July 17th. BMO Capital Markets upgraded Pfizer from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $33.00 to $37.00 in a report on Wednesday, August 2nd. UBS AG reiterated a “buy” rating and set a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Finally, Zacks Investment Research cut Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $38.15.
Shares of Pfizer (NYSE:PFE) traded up 0.823% during mid-day trading on Thursday, hitting $36.125. 3,946,620 shares of the stock were exchanged. The company has a 50-day moving average price of $35.41 and a 200-day moving average price of $33.80. Pfizer has a 12 month low of $29.83 and a 12 month high of $36.60. The stock has a market cap of $214.85 billion, a price-to-earnings ratio of 26.426 and a beta of 1.00.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Northstar Group Inc. raised its position in shares of Pfizer by 0.4% during the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 35 shares in the last quarter. Peregrine Asset Advisers Inc. raised its position in shares of Pfizer by 0.5% during the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC raised its position in shares of Pfizer by 0.8% during the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after acquiring an additional 50 shares in the last quarter. River Wealth Advisors LLC raised its position in shares of Pfizer by 0.3% during the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after acquiring an additional 55 shares in the last quarter. Finally, Meridian Wealth Management LLC raised its position in shares of Pfizer by 0.5% during the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after acquiring an additional 57 shares in the last quarter. 68.98% of the stock is currently owned by institutional investors and hedge funds.
In other news, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock valued at $15,813,961 in the last quarter. Company insiders own 0.06% of the company’s stock.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.57%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is presently 94.12%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.